Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Stockholm South General Hospital | OTHER |
| Karolinska University Hospital | OTHER |
| Danderyd Hospital | OTHER |
| University Hospital, Linkoeping |
Not provided
Not provided
Not provided
International guidelines recommend immediate reperfusion with systemic thrombolysis (ST) as first-line treatment in high-risk pulmonary embolism (PE). The therapy improves hemodynamics and overall survival but is also associated with a significant risk of severe bleeding. Catheter-directed intervention (CDI) is recommended as an alternative reperfusion therapy in high-risk PE when ST is contraindicated or has failed, as well as in patients who deteriorate or fail to improve during anticoagulation (AC) treatment. Despite lack of high-quality evidence and randomized studies between CDI and standard care, the use of CDI is spreading rapidly in high-risk PE and in less severe PE not fulfilling current treatment criteria.
Several CDI methods are available, including mechanical thrombectomy (MT) and catheter-directed thrombolysis (CDT), but no method is currently recommended over the other. In Sweden, the MT device FlowTriever® (FT) was introduced in 2021 and has since then been the predominant method. Industry sponsored trials have investigated FT in uncontrolled observational trials and primarily in intermediate-risk PE. The investigator-initiated research on FT is limited to relatively small, descriptive, single-arm studies, or trials focusing on intermediate-risk PE.
There are several ongoing trials comparing different CDI methods to anticoagulation. However, in clinical practice, patients with acute PE may be subjected to different reperfusion strategies depending on severity and available resources. The PE-NORDIC observational study will compare the outcomes of different patient groups treated with current CDI methods used in the Nordic countries to patients treated with ST.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Catheter-directed intervention | Catheter-directed intervention, any device |
| |
| Systemic thrombolysis | Intravenous thrombolysis with tissue-type plasminogen activator (tPA) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Catheter directed intervention, any device | Procedure | Catheter directed intervention for treatment of pulmonary embolism |
|
| Measure | Description | Time Frame |
|---|---|---|
| Composite of severe bleeding or mortality at 30 days | A composite of severe bleeding according to GUSTO (defined as intracranial bleeding or bleeding with substantial hemodynamic com-promise requiring treatment) or death within 30 days after treatment | From treatment to day 30 after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | Incidence of all-cause mortality | 30 days |
| Mortality | Cause of death | 30 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Pulmonary embolism patients treated with catheter directed intervention or systemtic thrombolysis in hospitals in Sweden and Denmark where the former treatment modality is established.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Freyr Einarsson, MD | Contact | +46500 43 10 36 | freyr.einarsson@vgregion.se | |
| Annika Odenstedt, coordinator | Contact | +46 343 53 94 | annika.odenstedt@vgregion.se |
| Name | Affiliation | Role |
|---|---|---|
| Kristina Svennerholm, Assoc Prof | Sahlgrenska University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Aarhus University Hospital | Recruiting | Aarhus | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41812431 | Derived | Einarsson Askeli F, Andersen A, Glise Sandblad K, Martinell L, Pivodic A, Rylander C, Tavoly M, Svennerholm K; PE-NORDIC Investigators. Reperfusion treatment strategies in acute pulmonary embolism: Study protocol for a multicenter prospective observational study in the Nordic countries (PE-NORDIC). Thromb Res. 2026 Apr;260:109635. doi: 10.1016/j.thromres.2026.109635. Epub 2026 Mar 3. |
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | May 20, 2025 | Nov 7, 2025 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jul 17, 2025 | Nov 7, 2025 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D011655 | Pulmonary Embolism |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D004617 | Embolism |
| D016769 | Embolism and Thrombosis |
Not provided
Not provided
| ID | Term |
|---|---|
| D010959 | Tissue Plasminogen Activator |
| ID | Term |
|---|---|
| D012697 | Serine Endopeptidases |
| D010450 | Endopeptidases |
| D010447 | Peptide Hydrolases |
| D006867 | Hydrolases |
Not provided
Not provided
| OTHER |
| Sunderby Hospital | OTHER |
| Aarhus University Hospital | OTHER |
| Örebro University, Sweden | OTHER |
| Odense University Hospital | OTHER |
| Skane University Hospital | OTHER |
| Rigshospitalet, Denmark | OTHER |
Not provided
Not provided
Not provided
| Alteplase | Drug | Systemic thrombolysis |
|
| Bleeding | Defined by GUSTO criteria, severe/non-severe. | 30 days |
| Rescue treatment | Incidence of rescue treatment for PE (Systemic thrombolysis/Catheter-directed intervention/extracorporeal membrane oxygenation (ECMO)/surgical embolectomy) | 30 days |
| Recurrent PE | Clinically relevant recurrence of PE | 30 days |
| Hospital free days | Hospital free days between treatment and 30 days | 30 days |
| ICU/HDU free days | Intensive care unit (ICU) and/or high dependency unit (HDU) free days between treatment and 30 days | 30 days |
| Change in RV/LV ratio | Change in right ventricular to left ventricular (RV/LV) diameter ratio before and within 72 h after treatment. | 72 hours |
| RV dysfunction | Examined by echocardiogram in association with follow-up visit 1 and 2 | 1 year |
| Persisting dyspnea | Self-reported level of dyspnea at follow-up visit 1 compared to discharge date and at follow-up visit 2 to compared to visit 1. | 1 year |
| 6-minute walk test | Distance (meters) walked in a 6-minute walk test performed at follow-up visit 1 and 2 | 1 year |
| Sit-to-stand 60 test | Number of stand-ups performed in a sit-to-stand 60 test performed at follow-up visit 1 and 2 | 1 year |
| PEmb-QoL | Pulmonary Embolism Quality of Life Questionnaire. Disease-specific health-related quality of life. FC: Frequency of complaints (8 items, reverse scoring where lower scores correspond to better quality of life). AD: Activities of daily living limitations (13 items, reverse scoring where lower scores correspond to better quality of life). WR: Work-related problems (4 items, reverse scoring where lower scores correspond to better quality of life). SL: Social limitations (1 item). IC: Intensity of complaints (2 items). EC: Emotional complaints (10 items, reverse scoring where lower scores correspond to better quality of life). | 1 year |
| MRC dyspnoea scale | Medical research council dyspnoea scale. 0-4, a higher number corresponds to more dyspnoea. | 1 year |
| EQ-5D-5L | EuroQol 5-dimension 5-level questionnaire. Generic health-related quality of life assessment. Movement (1-5), 1 corresponds to high and 5 to low movement level (descriptive) Care (1-5), 1 corresponds to high and 5 to low care level (descriptive) Activity (1-5), 1 corresponds to high and 5 to low activity level (descriptive) Pain (1-5), 1 corresponds to low and 5 to high pain level (descriptive) Anxiety (1-5), 1 corresponds to low and 5 to high anxiety level (descriptive) EQ-VAS (0-100), where 0 corresponds to worst health and 100 to best possible | 1 year |
| PVFS scale | Post venous thromboembolism functional status scale (0-4) 0 corresponds to not affected of thromboembolism daily, 4 severely affected in daily life. | 1 year |
| Incidence of CTEPH | Incidence of chronic thromboembolic pulmonary hypertension (CTEPH) | 1 year |
| Cardiac biomarkers | Troponin and NTproBNP | 1 year |
| Rigshospitalet | Recruiting | Copenhagen | Denmark |
|
| Odense University Hospital | Recruiting | Odense | Denmark |
|
| Sahlgrenska University Hospital | Recruiting | Gothenburg | 41345 | Sweden |
|
| Linköping University Hospital | Recruiting | Linköping | Sweden |
|
| Sunderby Hospital | Recruiting | Luleå | Sweden |
|
| Skåne University Hospital | Recruiting | Lund | Sweden |
|
| Örebro University Hospital | Recruiting | Örebro | Sweden |
|
| Danderyd Hospital | Recruiting | Stockholm | Sweden |
|
| Karolinska University Hospital Huddinge | Recruiting | Stockholm | Sweden |
|
| Karolinska University Hospital Solna | Recruiting | Stockholm | Sweden |
|
| Södersjukhuset | Recruiting | Stockholm | Sweden |
|
| Uppsala University Hospital | Not yet recruiting | Uppsala | Sweden |
|
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D004798 |
| Enzymes |
| D045762 | Enzymes and Coenzymes |
| D057057 | Serine Proteases |
| D010960 | Plasminogen Activators |
| D001779 | Blood Coagulation Factors |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D001685 | Biological Factors |